1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Genexine, Inc.

Genexine, Inc.

095700.KQ
Genexine, Inc.KR flagKOSDAQ
2,415.00
KRW
+105.00
- -
109.83BMarket Cap
Genexine, Inc.
095700.KQ
(KOSDAQ)

Recent

price

2,415.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
83.85
206.39
427.76
331.26
840.97
1,531.18
507.34
1,111.53
455.03
380.72
555.23
1,061.65
494.45
109.36
69.56
100.5
102.66
Revenue per Share
-166.68
-547.03
-143.42
-518
-374.31
-67.17
-1,382.44
-755.08
-1,203.39
-556.07
825.49
-1,375.81
-1,714.88
-1,652.14
-1,511
-598
-455.92
Basic EPS, GAAP
-1,191.85
-791.08
-614.32
-937.47
-686.37
-1,032.62
-856.5
-1,820.77
-991.34
-1,571.41
-1,401.5
-2,010.75
-2,192.97
-1,122.45
-683.19
-974.37
-926.24
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-56.04
-1,421.62
-1,385.99
-1,688.86
-1,833.55
-1,768.27
-4,363.37
-4,519.3
-5,296.11
-5,556.63
-4,240.1
-4,374.57
-6,710.77
-7,803.42
-2,054
-2,520.71
-2,892.5
Book Value per Share
1,951.4
1,820.38
2,704.17
1,560.19
4,024.19
4,224.23
5,568.43
4,285.86
11,137.77
9,845.71
15,943.06
14,989.85
8,435.66
7,285.31
5,524.89
4,854.76
4,496.97
Tangible Book Value per Share
13
13
15
17
20
21
22
26
28
30
33
35
33
40
42
46
45
Basic Weighted Avg Shares
1,079
2,661
6,252
5,755
16,656
32,520
11,352
28,455
12,882
11,303
18,543
36,828
16,139
4,427
2,933
4,574
4,669
Sales/Revenue/Turnover
-162.32
-216.28
-43.07
-122.52
-31.27
3.34
-272.07
-94.39
-295.64
-393.94
-211.13
-51.86
-208.68
-931.65
-1,268.55
-788.67
-785.15
Operating Margin (%)
431
725
3,433
4,435
6,561
3,607
2,547
2,650
2,283
2,503
2,920
3,298
4,872
5,031
5,434
7,034
7,206
Depreciation Expense
-2,146
-7,054
-2,096
-8,999
-7,413
-1,427
-30,933
-19,330
-34,067
-16,509
27,570
-47,727
-55,974
-66,874
-63,706
-27,215
-20,735
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-198.79
-265.05
-33.53
-156.37
-44.51
-4.39
-272.49
-67.93
-264.46
-146.06
148.68
-129.59
-346.82
-1,510.71
-2,172.23
-595.01
-444.09
Profit Margin (%)
16,026
1,805
14,748
-6,767
44,402
28,690
45,809
15,941
166,691
73,179
-19,571
-1,880
-26,549
37,633
-7,056
-71,008
-83,441
Working Capital
6,898
- -
9,313
- -
4,257
- -
- -
11,458
34,610
29,214
15,964
40,788
18,651
22,734
27,133
6,599
5,611
LT Debt
36,886
24,043
45,825
38,303
100,932
125,766
130,125
113,909
320,507
296,909
536,533
523,273
277,394
296,904
261,681
246,755
229,656
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-8.72
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-25.53
- -
- -
- -
- -
- -
-1,288.36
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
57,782
101,251
98,688
LT Borrowings
37,262
6,557
5,573
LT Finance Leases
46
42
38
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
45
45
Market Capitalization
251,067
213,089
210,571

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
38,296
45,851
35,401
Cash, Cash Equivalents & STI
22,209
34,949
24,214
Accounts Receivable, Net
98
300
222
Inventories
- -
- -
- -
Total Current Liabilities
65,828
116,859
118,843
Payables & Accruals
- -
- -
- -
ST Debt
57,782
101,251
98,688
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.57%
-12%
-5.7%
Free Cash Flow
18.98%
6.49%
53.95%
Net Income, GAAP
149%
-59.68%
-57.28%
Sales/Revenue/Turnover
7.47%
-1.59%
55.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,073
344
209
306
2,933
2025
320
672
3,046
537
4,574
2026
415
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-279.03
-292
-351
- -
-1,511
2025
-416
-323.29
462.89
- -
-598
2026
-273.62
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Opiant Pharmaceuticals, Inc. (OPNT)
PCI Biotech Holding ASA (PCIB.OL)
Faron Pharmaceuticals Oy (FARN.L)
NewAmsterdam Pharma Company N.V. (NAMSW)
tella, Inc. (2191.T)
Verve Therapeutics, Inc. (VERV)
Business
Genexine, Inc. (095700.KQ) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative immunotherapeutics, next-generation long-acting biologics, and targeted protein degradation therapies using its proprietary hyFc fusion platform, DNA vaccine platform, and bioPROTAC technology; key pipeline products include GX-H9 (eftansomatropin alfa), in Phase II/III trials for growth hormone deficiency; GX-E4, in Phase III trials for anemia associated with chronic kidney disease; GX-G3, in Phase II trials for neutropenia; GX-I7 (efineptakin alfa), in Phase I/II trials for solid tumors, lymphopenia, and other indications; GX-P1, in Phase I for autoimmune diseases and transplantation; GX-G6, in Phase II for diabetes; and GX-188E (tirvalimogene teraplasmid), in Phase II for cervical and head and neck cancers. Founded in 1999 and headquartered in Seoul, South Korea, the company operates primarily in the biotechnology sector targeting oncology, rare diseases, immune disorders, and biobetters, with clinical programs advancing in South Korea and international partnerships enhancing global development efforts. In recent developments, Genexine completed a merger with EPD Biotherapeutics in September 2024 through a small-scale merger with a 1:6.1924079 ratio, integrating bioPROTAC targeted protein degradation technology and appointing Jaehyun Choi, Ph.D., founder and CEO of EPD Bio, as head of R&D to bolster its pipeline; the company also maintains strategic alliances with global partners for joint R&D and clinical advancement of its immunotherapies.